Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 9, 2009, Pages 570-578

  Malhotra, Bimal K ^a   Wood, N ^b   Sachse, R ^c  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c Schwarz Pharma AG   (Germany)

Author keywords

Age; Fesoterodine; Gender; Pharmacokinetics; Race; Safety

Indexed keywords

FESOTERODINE; BENZHYDRYL DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NEGRO; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SEX DIFFERENCE; SINGLE DRUG DOSE; URINE VOLUME; XEROSTOMIA; ADOLESCENT; AGED; AGING; DRUG EFFECT; ETHNIC GROUP; MIDDLE AGED; PHYSIOLOGY; SALIVATION; SEXUAL DEVELOPMENT; URODYNAMICS;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGING; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; DOUBLE-BLIND METHOD; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SALIVATION; SEX CHARACTERISTICS; URODYNAMICS; YOUNG ADULT;

EID: 70349908417     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47570     Document Type: Article

References (25)

1. Brynne N, Stahl MM, Hallen B, Edlund PO, Palmer L, Hoglund P, Gabrielsson J. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther. 1997; 35: 287-295.
2. Cawello W, Auer S, Hammes W, Sachse R, Horstmann R. Multiple dose pharmacokinetics of fesoterodine in human subjects [abstract]. Naunyn Schmiedebergs Arch Pharmacol. 2002; 365: 428.
3. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: a safety update. Drugs Future. 2004; 29: 715-720.
4. Detrol LA® (tolterodine tartrate). Full Prescribing Information, Kalamazoo, MI: Pharmacia & Upjohn Company; 2005.
5. Ditropan® (oxybutynin chloride). Full Prescribing Information, Mountain View, CA: ALZA Corporation; 1998.
6. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005; 44: 701-720.
7. Enablex® (darifenacin hydrobromide). Full Prescribing Information, Stein, Switzerland: Novartis Pharma Stein AG; 2005.
8. Guay DR. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet. 2003; 42: 1243-1285.
9. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent). 2007; 20: 307-314.
10. Hughes KM, Lang JC, Lazare R, Gordon D, Stanton SL, Malone-Lee J, Geraint M. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 1992; 22: 859-869.
11. Krauwinkel WJ, Smulders RA, Mulder H, Swart PJ, Taekema-Roelvink ME. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther. 2005; 43: 227-238.
12. Laniado ME, Ockrim JL, Marronaro A, Tubaro A, Carter SS. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int. 2004; 94: 1283-1286.
13. Malhotra BK, Guan Z, Wood N, Gandelman K. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008; 46: 556-563.
14. Malhotra B, Gandelman K, Sachse R, Wood N. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. J Clin Pharmacol. 2009; 49: 477-482.
15. Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P. Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther. 2007b; 81: 377-385.
16. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004; 57: 6-14.
17. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008; 9: 1787-1796.
18. Nilvebrant L. The mechanism of action of tolterodine. Rev Contemp Pharmacother. 2000; 11: 13-27.
19. Nilvebrant L. Clinical experiences with tolterodine. Life Sci. 2001; 68: 2549-2556.
20. Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet. 2001; 40: 227-235.
21. Sanctura® (trospium chloride). Full Prescribing Information, Espirit Pharmaceuticals, NJ and Indevus Pharmaceuticals, MA, 2006.
22. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999; 24: 339-346.
23. VESIcare® (solifenacin succinate). Full Prescribing Information, Astella Pharma Technologies, Inc., Norman, OK, and GlaxoSmithKline, Research Triangle Park, NC, 2007.
24. Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch Neurol. 2003; 60: 771-773.
25. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001; 41: 815-850.